Skip to Content

Enzon Pharmaceuticals Inc ENZN

Morningstar Rating
$0.08 +0.01 (7.75%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

ENZN is trading at a 65% discount.
Price
$0.07
Fair Value
$5.35
Uncertainty
Extreme
1-Star Price
$6.28
5-Star Price
$1.69
Economic Moat
Ltfgy
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ENZN is a good fit for your portfolio.

Trading Information

Previous Close Price
$0.07
Day Range
$0.080.08
52-Week Range
$0.060.23
Bid/Ask
$0.07 / $0.09
Market Cap
$5.79 Mil
Volume/Avg
125 / 19,744

Key Statistics

Price/Earnings (Normalized)
7.24
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Enzon Pharmaceuticals Inc is positioned as a public company acquisition vehicle, where the Company can become an acquisition platform and more fully utilize its net operating loss carryforwards and enhance stockholder value.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees

Competitors

Valuation

Metric
ENZN
VRTX
RHHBY
Price/Earnings (Normalized)
7.2426.2711.10
Price/Book Value
1.535.865.52
Price/Sales
10.552.89
Price/Cash Flow
4.4227.3910.64
Price/Earnings
ENZN
VRTX
RHHBY

Financial Strength

Metric
ENZN
VRTX
RHHBY
Quick Ratio
27.433.600.99
Current Ratio
27.623.991.35
Interest Coverage
86.3814.93
Quick Ratio
ENZN
VRTX
RHHBY

Profitability

Metric
ENZN
VRTX
RHHBY
Return on Assets (Normalized)
2.92%19.46%17.03%
Return on Equity (Normalized)
45.09%25.47%53.42%
Return on Invested Capital (Normalized)
−13.57%21.34%26.30%
Return on Assets
ENZN
VRTX
RHHBY
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRHfdjglrwqlJkjbx$557.8 Bil
VRTX
Vertex Pharmaceuticals IncQpccljlsDsprc$103.3 Bil
REGN
Regeneron Pharmaceuticals IncXfgxpcpchNhqmjr$98.8 Bil
MRNA
Moderna IncKqxpjrzkZhcfh$38.8 Bil
ARGX
argenx SE ADRJxpknkqmWtvl$21.3 Bil
BNTX
BioNTech SE ADRZgvrcsvdhBrjr$20.8 Bil
ALNY
Alnylam Pharmaceuticals IncRyyktlttjGctxd$18.4 Bil
BMRN
Biomarin Pharmaceutical IncMlrvlnvwKlmrg$17.0 Bil
RPRX
Royalty Pharma PLC Class AYrngvzpndSpmydj$12.4 Bil
INCY
Incyte CorpGrnpvstthZwsnhk$11.9 Bil

Sponsor Center